Implementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.
Patients with diabetes and stress hyperglycemia are frequently hospitalized for surgical procedures,1and recent estimates indicate that 30% to 50% of US inpatients have diabetes and/or hyperglycemia.1,2Multiple studies have documented the risks of perioperative hyperglycemia, including poor surgical outcomes and higher readmission rates.1-4However, improved glycemic control leads to reductions in hospital complications, length of stay, and mortality.1,5-7
Multiple professional societies, agencies, and task forces have issued guidelines recommending methods to achieve safe and effective glycemic control in hospitalized patients.8-12Although the optimal target glucose range for hospitalized patients continues to evolve based on results of recent clinical trials,10,13,14achieving moderate glycemic control is also beneficial to surgical patients.15-17Surgical populationsas opposed to medically ill patient populations—seem to be at lower risk for hypoglycemia and are able to derive benefit from inpatient glucose control.9,18-21
Despite the potential benefits of improved glucose control for surgery patients, patients admitted to hospitals for any cause, including surgical services, may not receive optimal glycemic management. The challenges to creating and implementing a perioperative glycemic control program are numerous and well-recognized.8,13,22The clinical expertise necessary for prescribing and adjusting appropriate insulin regimens in patients with rapidly changing needs may not be readily available to all surgical patients.23,24Patient safety advocates predict that expanding the roles of nonphysician health professionals (eg, pharmacists) will be central to the success of new healthcare delivery models in optimizing quality and providing timely evidence-based care.25
In an effort to improve care in our dysglycemic surgical population, we created a dedicated glycemic control team (GCT) responsible for writing insulin orders and coordinating all aspects of glucose control perioperatively.21The objective of this implementation research analysis was to evaluate the effectiveness of the GCT with respect to: a) inpatient glycemic control; and b) post surgical outcomes, including wound infection and all-cause hospital readmissions, postdischarge emergency department (ED) utilization, and postdischarge medical costs. Glycemic control in the perioperative setting at our hospital had been managed at the discretion of each patient’s individual surgeon and/or anesthesiologist, and approaches to glucose control were highly variable in the management of perioperative hyperglycemia when it was identified.
This study was reviewed and approved by the Kaiser Permanente Northwest (KPNW) Center for Health Research Institutional Review Board.
We developed and implemented a GCT at Kaiser Sunnyside Medical Center (KSMC) in Clackamas, Oregon. KSMC is a tertiary care hospital and part of KPNW, a nonprofit health maintenance organization with about 485,000 members in southwest Washington and the Portland, Oregon, metropolitan area. KPNW’s regional EpicCare-based electronic medical record (EMR) provides highly sensitive integrated data on patient membership, demographics, primary care assignment, and clinical data (including weight and height, laboratory results, and healthcare utilization).
The study population included all surgical inpatients admitted to the post anesthesia care unit (PACU) who also had 2 or more point-of-care test (POCT) glucose measurements during the 24-hour period (day 1) following the index PACU admission. To assess hypoglycemia and hyperglycemia, we measured POCT glucose measurements during days 1 to 3 following the PACU admission date. By identifying patients using PACU admission, we included all surgical patients being admitted to the hospital, except for 2 groups: cardiovascular surgery patients and critically ill surgical patients, since in our hospital, those patients are admitted directly to the intensive care unit from the operation room. Our evaluation population is thus congruent with the GCT’s target population (ie, noncardiovascular, noncritically ill, postoperative patients with glycemic control opportunities).
Cardiovascular surgery patients and critically ill patients were excluded from the evaluation analysis.
Description of GCT Intervention
The development and implementation of the GCT pharmacist program and protocol for management of hyperglycemia has been described previously. The glycemic control team was deployed in January 2009. As described by Mularski and colleagues (2012)21:
“The GCT protocol was created by a pharmacy clinical coordinator who worked closely with physicians experienced in diabetes management from the Endocrinology, Hospitalist, and Surgery Departments. The protocol was designed to direct the safe and appropriate use of intravenous (IV) and subcutaneous insulin in surgical and medical patients with diabetes or risk of developing hospital hyperglycemia. Important components of the protocol included recommendations on when to begin and discontinue IV insulin, how to transition from IV therapy, how to calculate subcutaneous insulin doses, how to adjust insulin doses, when to resume oral agents, how to manage patients on tube feedings and total parental nutritional, and discharge planning. The GCT protocol allows the GCT pharmacist to provide comprehensive inpatient glycemic management. In addition to writing and adjusting daily insulin orders, the GCT can also order relevant labs (glycated hemoglobin [A1C]), place consultation requests for a registered dietician and/or diabetes educator, and via verbal collaboration with clinicians place discharge orders for insulin and diabetic supplies.”
Trained inpatient pharmacists were available, on a consultation basis, 7 days a week, to any surgical patient requiring perioperative glycemic control management.
Position Duties and Work Flow
The GCT was usually consulted in the immediate post anesthesia phase upon recognition of stress hyperglycemia or for ongoing management of known diabetes. Regarding day-to-day work flow, Mularski (2012) notes21:
“After reviewing the patient’s chart and meeting with the patient’s nurse, the GCT pharmacist enters insulin orders into the EMR order entry system. All of the following are available to the GCT pharmacist: the POCT glucose results, laboratory test values, electronic medication administration record, all clinician notes, and outpatient records (including medication orders, chart notes, and laboratory test results). After entering necessary orders for all patients, the GCT pharmacist meets with most of the patients to obtain history from new patients or, especially for patients without known diabetes, to explain why blood glucose is tested, and why they are receiving insulin during their hospitalization. The GCT pharmacist also gathers home blood glucose control information and identifies barriers to good outpatient control.”
Mularski et al also describes the hospital discharge process, noting:
“Discharge glycemic control needs are addressed as early in the hospitalization as clinically feasible to allow for needed patient education and planning patients’ transition regimens. Patients who have discharge needs (eg, patients with new insulin starts or patients with poor control) receive interventions by the GCT pharmacist and coordination of care from the health care team. In general, the GCT pharmacist is responsible for: communicating the discharge plan to the patient; providing basic education and reviewing signs or symptoms of hypoglycemia and its management; constructing a discharge instruction sheet for new insulin starts; obtaining authorization from the attending physician regarding the discharge plan; entering discharge orders for outpatient regimens; electronically routing progress notes to the primary care physician; communicating with floor nurses to provide glucometer teaching (if indicated); and communicating with the certified diabetes educator; who provides more in-depth, individualized diabetes education.”
We considered the period between January 1 and June 30, 2009, to be the implementation phase when key staff became familiar with the GCT program. By July 1, 2009, the GCT program was fully implemented, with the pharmacist team using 2 full-time inpatient pharmacists and operating 7 days a week, 10 hours per day. After hours, an on-call hospitalist addressed new consults and urgent issues, with subsequent care and follow-up assumed by the GCT pharmacists the following morning. Hospitalist or endocrinologist supervision was available and was required for complex or unusual cases that did not fall clearly under the KPNW protocol during all hours of the day. Inpatient nurses performed bedside POCT glucose testing and administered scheduled insulin per orders. Nurses followed established written protocols for IV insulin adjustments on an hourly basis. GCT pharmacists reviewed POCT glucose results at least daily and made appropriate adjustments to ordered insulin regimens as needed during daytime hours.
Research Design and Study Outcomes
We used a retrospective, observational study design to evaluate the effectiveness of the intervention on study outcomes. The pre-implementation period was designated as the 12 months prior to the GCT implementation: January 1 through December 31, 2008. The post implementation periodafter the GCT team was fully implemented at KSMC—included the 24 months from July 1, 2009, through June 30, 2011.
We obtained all data elements from KPNW’s EMR.
Glycemic control process measures.We analyzed 2 measures of glycemic control whose definitions were reported elsewhere21: a) good glycemic control: defined as having all, or all but one, POCT glucose values between 70 and 180 mg/dL in the first 24-hour period (day 1) following the PACU admission date; b) hypoglycemia: defined as having any POCT glucose value less than 70 mg/dL during days 1 to 3 following the PACU admission date.
Utilization outcome measures.We defined 3 clinical patient-centered outcome measures related to utilization: a) wound-infectionrelated hospital readmissions: any wound-infection hospital readmission within 90 days after index surgical hospital discharge date (International Classification of Diseases, Ninth Revision, Clinical Modificationcodes 998.59, 674.30, 674.32, or 674.34; primary/secondary diagnosis); b) all-cause hospital readmissions within 90 days after the index surgical hospital discharge date; c) ED utilization within 90 days after the index surgical hospital discharge date.
Cost outcome measures.We measured total medical costs in the 6 months (182 days) after index hospital discharge date. All cost information was measured in 2011 US$ and is reported as postdischarge per patient per month (PPPM) costs. Actual health plan costs for each person were extracted from administrative data; the methods for this analysis have been reported elsewhere.26
Covariates.To adjust for possible effects of comorbidity and contributory factors, we constructed the following covariate measures from existing comprehensive EMR data: a) demographics and socioeconomic status (SES) (ie, age as of index date [continuous], gender, race [white, nonwhite, unknown]), and an approximation of low SES designated as poverty status (assessed using 2010 Census information, measured as a dichotomous variable based on income/federal poverty level (FPL) (household income ≤100% FPL vs >100% FPL); b) severity of illness (adjusted by the Charlson comorbidity index [CCI] scorea well-established comorbidity measure27,28) and average length of stay (ALOS) for index hospitalization; c) prior utilization (2 measures of prior healthcare utilization including hospital admissions [≥1 admission vs none] and ED visits [≥1 visit vs none]; d) to approximate for case risk and differences in care across different subspecialty groups, we developed a surgery-service categorization using 10 groups (general surgery, orthopedics, gynecology, urology, spine, thoracic, podiatric, neurosurgical, vascular, and other), which were constructed by reviewing frequencies of Current Procedural Terminology codes conducted at KSMC and grouping surgeries into subspecialty categories; and e) to assess risk of perioperative hyperglycemia, we applied a preexisting approximation for prior hyperglycemia using A1C status, operationalizing a dichotomous variable from A1C value taken closest to index hospital admission date and categorized into 2 groups: A1C ≥6.5% vs A1C< 6.5% or untested, suggesting lack of underlying identified risk of hyperglycemic state.
We used χ2analysis to assess differences in glycemic control and utilization metrics between the post implementation periods (year 1 and year 2) versus the pre-implementation period. To account for the effect of potential confounders, we further performed logistic regression analysis to measure the independent effect of the GCT intervention with study outcomes using 2 approaches.
For the 2 glycemic control outcome measures, we adjusted logistic models for: age (continuous), gender, race/ethnicity (nonwhite vs white [reference group]), poverty status (≤100% FPL vs >100% FPL [reference group]), CCI score (continuous), surgery type (ie, orthopedic, gynecology, urology, spine, thoracic, neurosurgery, vascular, other/unknown vs general surgery [reference group]), ≥1 prior ED visits (vs none [reference group]), ≥1 prior hospital admissions (vs none [reference group]), ALOS for index hospitalization (continuous), and risk status for perioperative hyperglycemia
(A1C ≥6.5% vs A1C <6.5%/untested [reference group]). The same covariate measures were included for the 3 utilization outcome measures, with the addition of good glycemic control (day 1) versus poor control (reference group).
The study population totaled 11,553 unique patients: 1277 in the pre-intervention period, 4811 in year 1 post intervention, and 5465 in year 2 post intervention.presents demographics, clinical characteristics, utilization, and type of surgery classification among the study population. In the post intervention periods, the average age was approximately 4 years younger and a slightly higher proportion was female compared with the pre-intervention period. Also, both the CCI index and utilization (hospital admissions and ED utilization) 12 months prior to index admission were lower in the post intervention periods (year 1 and year 2), compared with the pre-intervention period. Similarly, there was a lower proportion of patients with A1C values ≥6.5% in the post intervention periods (year 1 and year 2), compared to the pre-intervention period. Last, there were fewer general surgeries in the post intervention period, offset by more orthopedic, gynecologic, urologic, and spine surgeries in the post intervention periods (year 1 and year 2).
presents a bivariate analysis of the study outcomes, andandpresent multivariate results. The proportion of patients with good glycemic control increased significantly in both bivariate and multivariate analysis. Patients were more likely to have good glycemic control (day 1) in year 1 (OR, 2.24; 95% CI, 1.85-2.72;P<.0001) and year 2 (OR, 2.19; 95% CI, 1.81-2.66;P<.0001) after implementation of the GCT, compared to the preintervention period after adjusting for covariates. In addition, the proportion of patients with hypoglycemia in days 1 to 3 declined significantly in both bivariate and multivariate analysis. Patients were less likely to have hypoglycemia in year 1 (OR, 0.38; 95% CI, 0.31-0.46;P<.0001) and year 2 (OR, 0.31; 95% CI, 0.25-0.38;P<.0001) post intervention, compared with the pre-intervention period, even after adjusting for covariates.
The utilization metrics also showed significant reductions upon both bivariate and multivariate analysis. Compared to the pre-intervention period, wound-infectionrelated readmissions declined significantly in year 2 (OR, 0.51; 95% CI, 0.29-0.91;P= .031), all-cause hospital readmissions declined in year 1 (OR, 0.69; 95% CI, 0.56-0.86;P= .03) and year 2 (OR, 0.67; 95% CI, 0.54-0.85;P= .008), and all-cause postdischarge ED utilization declined significantly in year 1 (OR, 0.71; 95% CI, 0.60-0.84;P= .003) and year 2 (OR, 0.72; 95% CI, 0.60-0.85;P= .009), compared to the pre-intervention period and adjusting for covariate measures. Finally, postdischarge PPPM costs were lower in both bivariate and multivariate analyses. PPPM costs were lower in year 1 (parameter estimate = 208.8;P<.0001) and year 2 (parameter estimate = 283.5;P= .010) post intervention compared with the pre-intervention period and adjusting for covariate measures.
Our previously published report showed that improvements in the quality and safety of perioperative glycemic control could be achieved by implementing a pharmacist-run glycemic management team.21In this longitudinal analysis, our results suggest sustained improvement in measures of glycemic control in the second year following implementation of the team. The achieved level of control and low hypoglycemia rate in our study compare favorably with published results of hospitalized patients in other systems.29-32
Moreover, we found reduced postoperative ED visits, hospital readmissions, and total medical costs in the post implementation period, compared with the pre-implementation period. Reduced post surgical ED and hospital utilization and costs likely reflect an overall reduction in postoperative complications. These results may confirm the success of continuing to meet quality and safety goals with the GCT initiative. They may also demonstrate important correlations with patient-centered outcomes such as postdischarge problems requiring ED visits or repeat hospitalization, as well as reduced cost.
Results from our study are the first that we are aware of that may demonstrate the effectiveness of a pharmacist-run team to improve both: a) glycemic control measures and b) utilization and cost outcomes for surgical inpatients. Prior studies documented reduced utilization, namely improved hospital length of stay (LOS) for an inpatient population with diabetes,33,34but they did not examine costs. Other research found cost savings due to implementation of IV insulin with a target postoperative glucose <150 mg/dL after coronary bypass surgery ($680 per patient4) but did not examine utilization differences. Last, other research found that implementation of a comprehensive glucose management program reduced hyperglycemia and decreased LOS, but hospital costs were not changed.35
Our results have implications for dissemination and implementation of a glycemic control pharmacist program modeled after our GCT to other institutions. Research shows that implementation of evidence-based guidelines and recommended treatments are highly variable and inherently slow and gradual among clinicians and hospitals.35,36The results of our analysis demonstrate that, by developing a specific team of pharmacists whose sole purpose is to focus on inpatient glycemic management, perioperative and postoperative dysglycemia management can be improved.
Our quality-improvement evaluation has some important limitations. First, the population in the post intervention periods had slightly less acuity compared with the pre-intervention period, and it is possible that temporal changes account for some aspects of the improved outcomes, though multivariate analysis controlled for some patient-level variance. However, our concerns about these limitations are mitigated for several reasons. First, we robustly adjusted statistically for differences in the patient population over time, and our analyses demonstrated persistent main effects that remained statistically significant. Second, we found improvements in glycemic control (post intervention) that remained significant in a sub-analysis of patients with A1C >6.5% (results not shown). Additionally, a sensitivity analysis looking at all surgical patients during parallel time frames demonstrated outcome improvements proportional to the ratio of study population to all surgical patients, suggesting that other temporal effects do not account for the main beneficial effects. Nevertheless, it is possible that differences observed in key outcome measures may be due to imbalances between the 2 study population periods (post implementation vs pre-implementation), rather than the intervention per se. The imbalances between the 2 groups may also suggest unmeasured factors such as patient behaviors that are not possible to assess through the EMR. Nevertheless, despite rigorously adjusting for differences in the 2 study populations, the retrospective prepost observational design of the study limits the ability to assess the effectiveness of the GCT intervention. A prospective, randomized trial design would be ideal in future studies to assess the effectiveness of pharmacist-based GCT interventions.
Secondly, it is possible that the pharmacist team helped achieve improved outcomes due to factors that were not related to glycemic control. For instance, improved medication reconciliation and patient education for nonglycemic-related medications might have benefitted patients being followed by the GCT. However, our pharmacists were not tasked to provide these broader services under the protocol, and, given their limited scope, this seems unlikely to have had a major effect on nor be a detrimental effect of the program. In addition, because we did not have a control group available for analysis, results may have been attributed to secular trends, rather than the intervention per se.
A final limitation is that our intervention and evaluation were conducted at a single medical center within an integrated delivery system and our results may not apply to other settings or care delivery systems. This limitation is mitigated by anticipated generalizability to other hospital settings (eg, academic medical centers, community hospitals), given that the intervention was conducted in the inpatient setting where fewer differences exist across institutions. The inpatient pharmacists and staff who conducted the intervention would be found in most hospital settings in the United States.
Based on the initial success of the GCT, future research should examine the effectiveness of a glycemic pharmacist team intervention for nonsurgical patient populations with unmet glycemic control management needs in the hospital, such as oncology patients on high-dose steroid regimens. Future research should also study the effectiveness of the intervention across a variety of hospital systems (eg, Veterans Administration, academic medical centers) that serve more socioeconomically and ethnically diverse patient populations. Other ways to implement standardized, guideline-based treatment of perioperative hyperglycemia (such as automated nurse-initiated protocols) could also be explored. In addition, future research is needed to examine whether glycemic control outcomes differ among populations with stress hyperglycemia, compared with diabetes. In addition, more research is needed to understand the effect of GCT programs on future glycemic control post hospital discharge. Finally, prospective, randomized pragmatic and effectiveness trials are needed to refine our understanding of the ideal target glucose range for surgical patients, as well as of the best medical regimens (IV insulin, subcutaneous insulin, and noninsulin medications) to achieve glucose control targets for surgical subpopulations.
Implementation of a pharmacist-led GCT is associated with better inpatient glycemic control in perioperative patients and reduced postdischarge utilization and medical costs. These improvements persist when adjusted for multiple potential confounders in the populations studied.